Universal Biosensors, Inc.

ASX:UBI Stock Report

Market Cap: AU$46.7m

Universal Biosensors Past Earnings Performance

Past criteria checks 0/6

Universal Biosensors's earnings have been declining at an average annual rate of -59.4%, while the Medical Equipment industry saw earnings growing at 5.6% annually. Revenues have been declining at an average rate of 62.1% per year.

Key information

-59.4%

Earnings growth rate

-58.3%

EPS growth rate

Medical Equipment Industry Growth5.8%
Revenue growth rate-62.1%
Return on equity-34.6%
Net Margin-101.6%
Last Earnings Update31 Dec 2023

Recent past performance updates

Recent updates

We Think Universal Biosensors (ASX:UBI) Needs To Drive Business Growth Carefully

Nov 09
We Think Universal Biosensors (ASX:UBI) Needs To Drive Business Growth Carefully

We're Keeping An Eye On Universal Biosensors' (ASX:UBI) Cash Burn Rate

May 03
We're Keeping An Eye On Universal Biosensors' (ASX:UBI) Cash Burn Rate

We Think Universal Biosensors (ASX:UBI) Needs To Drive Business Growth Carefully

Jan 12
We Think Universal Biosensors (ASX:UBI) Needs To Drive Business Growth Carefully

We're Keeping An Eye On Universal Biosensors' (ASX:UBI) Cash Burn Rate

Oct 10
We're Keeping An Eye On Universal Biosensors' (ASX:UBI) Cash Burn Rate

Companies Like Universal Biosensors (ASX:UBI) Are In A Position To Invest In Growth

Apr 28
Companies Like Universal Biosensors (ASX:UBI) Are In A Position To Invest In Growth

We Think Universal Biosensors (ASX:UBI) Can Afford To Drive Business Growth

May 13
We Think Universal Biosensors (ASX:UBI) Can Afford To Drive Business Growth

Should You Take Comfort From Insider Transactions At Universal Biosensors, Inc. (ASX:UBI)?

Feb 24
Should You Take Comfort From Insider Transactions At Universal Biosensors, Inc. (ASX:UBI)?

We Think Universal Biosensors (ASX:UBI) Can Afford To Drive Business Growth

Jan 20
We Think Universal Biosensors (ASX:UBI) Can Afford To Drive Business Growth

The Universal Biosensors (ASX:UBI) Share Price Has Gained 95% And Shareholders Are Hoping For More

Dec 15
The Universal Biosensors (ASX:UBI) Share Price Has Gained 95% And Shareholders Are Hoping For More

Revenue & Expenses Breakdown
Beta

How Universal Biosensors makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

ASX:UBI Revenue, expenses and earnings (AUD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 237-7155
30 Sep 235-18157
30 Jun 234-20149
31 Mar 234-261310
31 Dec 225-271112
30 Sep 225-191013
30 Jun 225-16812
31 Mar 226-14711
31 Dec 216-1169
30 Sep 216-766
30 Jun 216-665
31 Mar 214-865
31 Dec 203-865
30 Sep 203-765
30 Jun 204-665
31 Mar 206-465
31 Dec 197-576
30 Sep 1914-886
30 Jun 19603588
31 Mar 196435710
31 Dec 186938712
30 Sep 186539713
30 Jun 1824-4813
31 Mar 1825-3713
31 Dec 1725-1711
30 Sep 17266711
30 Jun 17235711
31 Mar 17225611
31 Dec 16191613
30 Sep 1617-6614
30 Jun 1620-4715
31 Mar 1619-5718
31 Dec 1517-7717
30 Sep 1518-5618
30 Jun 1514-6618
31 Mar 1511-9617
31 Dec 1410-9617
30 Sep 148-12618
30 Jun 148-11617
31 Mar 1412-11616
31 Dec 1315-12615
30 Sep 1318-13716
30 Jun 1325-13716
31 Mar 1328-11716

Quality Earnings: UBI is currently unprofitable.

Growing Profit Margin: UBI is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: UBI is unprofitable, and losses have increased over the past 5 years at a rate of 59.4% per year.

Accelerating Growth: Unable to compare UBI's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: UBI is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (10.1%).


Return on Equity

High ROE: UBI has a negative Return on Equity (-34.56%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.